A PHASE IV, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE EFFECTS OF USTEKINUMAB ON VASCULAR INFLAMMATION IN PSORIASIS
Phase of Trial: Phase IV
Latest Information Update: 20 Aug 2019
Price : $35 *
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriasis; Vasculitis
- Focus Biomarker; Therapeutic Use
- Acronyms VIP-U
- 26 Nov 2018 Status changed from active, no longer recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 14 Jun 2017 Status changed from recruiting to active, no longer recruiting.